<DOC>
	<DOCNO>NCT00113763</DOCNO>
	<brief_summary>The purpose study determine panitumumab , use propose regimen , safely increase progression free survival patient metastatic colorectal cancer fail available treatment option ( i.e. , patient develop progressive disease relapse prior fluoropyrimidine , irinotecan oxaliplatin chemotherapy ) .</brief_summary>
	<brief_title>Evaluating Panitumumab ( ABX-EGF ) Plus Best Supportive Care Versus Best Supportive Care Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Pathologic diagnosis colorectal adenocarcinoma ( diagnostic tissue obtain tissue biopsy ) Metastatic colorectal carcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Documented evidence disease progression , follow treatment , fluoropyrimidine , irinotecan oxaliplatin chemotherapy metastatic colorectal cancer Radiographic documentation disease progression within 6 month follow recent chemotherapy regimen Unidimensionally measurable disease Tumor express epidermal growth factor receptor ( EGFr ) immunohistochemistry At least 2 3 prior chemotherapy regimen colorectal cancer Adequate hematologic , renal hepatic function Symptomatic brain metastasis require treatment History evidence interstitial pneumonitis pulmonary fibrosis Use systemic chemotherapy radiotherapy within 30 day prior enrollment Prior epidermal growth factor receptor ( EGFr ) target therapy Prior antitumor therapy include prior experimental agent approve antitumor small molecule biologics short ( less week ) serum half life within 30 day enrollment , prior experimental approve protein within 3 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Metastatic Colorectal Cancer , Colon</keyword>
	<keyword>Colorectal , Rectal Cancer , Cancer</keyword>
	<keyword>Metastatic , EGFr , Clinical Trial</keyword>
	<keyword>Panitumumab , ABX-EGF</keyword>
	<keyword>Immunex , Abgenix , Amgen</keyword>
</DOC>